Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") (Nasdaq:ARWR). Investors, who purchased or otherwise acquired shares between May 11, 2015 and November 8, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm before the January 17, 2017 lead plaintiff motion deadline.

If you purchased Arrowhead shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Arrowhead made false and misleading statements and/or failed to disclose: that its drug candidate ARC-520 was fatal at certain doses; that the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; that the Company overstated the approval prospects and commercial viability of ARC-520; and that as a result of the above, Arrowhead's public statements were materially false and misleading at all relevant times. On November 8, 2016, Arrowhead revealed that the U.S. Food & Drug Administration will be placing a clinical hold on its Heparc-2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study. When this information was released, shares of Arrowhead declined in value, causing investors harm.

If you wish to learn more about this lawsuit free of charge, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on

Copyright Business Wire 2010